Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New quadrivalent flu vaccine shows promise for little ones

NCT ID NCT04381689

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times

Summary

This phase 3 study tests a new quadrivalent seasonal influenza vaccine in healthy infants aged 6 months to under 3 years. The goal is to see if the vaccine triggers a strong immune response and is safe compared to an existing flu shot. About 245 children will take part, and researchers will measure antibody levels before and after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
quadrivalent seasonal influenza vaccine
What this could lead to
If successful, this could provide a safe and effective seasonal flu vaccine option for infants and toddlers.
What could go wrong
This is a mid-stage trial with 245 participants, so results may not apply to all children. The vaccine may not work as well as expected or could cause side effects like mild fever or soreness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

260 people

The number who actually took part.

Started

Oct 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 3 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy infants 'from 6 months to under 3 years of age (≥6 months and \<3 years) 2. Born after normal gestation period (which is more than 37 weeks) 3. A subject's legally acceptable representative has voluntarily decided on participation and provided written informed consent after receiving and understanding a detailed explanation on this study Exclusion Criteria: 1. A history of severe hypersensitivity reactions (e.g., anaphylaxis) to eggs, chicken, and other components of a vaccine including those derived from chicken 2. A history of influenza vaccination within 6 months prior to screening 3. Immuno dysfunction including immunodeficiency diseases or a family history thereof 4. A history of Guillain-Barre syndrome 5. Down's syndrome or cytogenetic disorders 6. Severe chronic diseases (e.g., cardiovascular diseases excluding controlled hypertension, respiratory diseases with respiratory failure, metabolic diseases, renal dysfunction, hemoglobinopathy, etc.) that, in the opinion of investigator, preclude a subject's participation in the study 7. Risk of serious bleeding from an IM injection such as hemophilia patients or those on anticoagulants 8. Acute fever with body temperature exceeding 38.0℃ within 72 hours prior to vaccination with the IP 9. Vaccinated with other vaccines within 28 days prior to screening 10. Received immunosuppressants or immune-modifying drugs within 3 months prior to screening ① Azathioprine, cyclosporin, interferon, granulocyte colony-stimulating factor (G-CSF), tacrolimus, everolimus, sirolimus, etc. ② Use of high-dose corticosteroids (e.g., continued use of prednisolone at a dose of ≥2 mg/kg/day in subjects weighing \<10 kg for 14 days or longer or at a dose of ≥20 mg/day in subjects weighing ≥10 kg for 14 days or longer). However, inhaled, intranasal, or topical corticosteroids are permitted regardless of their dose. 11. Prior use of immunoglobulin or blood products within 3 months prior to screening or their anticipated use during the study 12. Took antipyretics, analgesics, or non-steroidal anti-inflammatory drugs (NSAIDs) within 4 hours prior to vaccination with the IP 13. Participated in another clinical study within 6 months prior to screening 14. Determined ineligible based on other clinically significant medical or psychiatric findings by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Korea University ANSAN Hospital

    Ansan-si, Gyeonnggi-do, 15355, South Korea

  • The Catholic University of Korea, Bucheon St. Mary's Hospital

    Bucheon-si, Gyeonnggi-do, 15355, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.